We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

INTEGRA BIOSCIENCES AG

MicroRNAs Differentiate Between Primary and Metastatic Brain Tumors

By Labmedica staff writers
Posted on 21 Jul 2008
MicroRNAs were used to differentiate between primary and metastatic tumors of the brain.

MicroRNAs (miRNAs) are naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. MicroRNAs have been shown to have different expression profiles in various pathological conditions. These differences provide a novel diagnostic strategy for many diseases.

A study conducted by Rosetta Genomics' (Rehovot, Israel) scientist Nitzan Rosenfeld and colleagues from five different Israeli medical centers demonstrated microRNAs' potential to act as effective biomarkers that could be applied in a diagnostic test to identify primary tumors in patients with brain cancer. The study results, published in the June 8, 2008 online edition of Brain Pathology, describe the development and validation of microRNA expression profiles for characterization of brain malignancies.

MicroRNA expression was measured in RNA extracted from hundreds of formalin-fixed, paraffin-embedded (FFPE) samples of brain primary tumors and other tissues, as well as 60 samples of metastatic brain tumors. Two microRNAs, miR-92b and miR-9/9*, were found to be significantly over-expressed in brain primary tumors, and may represent potential biomarkers for the identification of these tumors. The study demonstrated, based on a blinded test set, that the overall sensitivity and specificity of this classifier are approximately 90%.

The study authors wrote: "By considering the expression of only these two microRNAs, it is possible to distinguish between primary and metastatic brain tumors with very high accuracy. These microRNAs thus represent excellent biomarkers for brain primary tumors. Previous reports have found that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are expressed more strongly in developing neurons and brain than in adult brain. Thus, their specific over-expression in brain primary tumors supports a functional role for these microRNAs or a link between neuronal stem cells and brain tumorigenesis.”


Related Links:
Rosetta Genomics

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Human Estradiol Assay
Human Estradiol CLIA Kit

Latest Molecular Diagnostics News

New Test Detects Alzheimer’s by Analyzing Altered Protein Shapes in Blood
21 Jul 2008  |   Molecular Diagnostics

New Diagnostic Markers for Multiple Sclerosis Discovered in Cerebrospinal Fluid
21 Jul 2008  |   Molecular Diagnostics

Cell-Free DNA Predicts Bloodstream Infections in Children with Leukemia
21 Jul 2008  |   Molecular Diagnostics